CTI BIOPHARMA CORP's ticker is CTIC and the CUSIP is 12648L601. A total of 57 filers reported holding CTI BIOPHARMA CORP in Q1 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $55,835 | -31.4% | 13,294 | -1.8% | 0.00% | – |
| Q4 2022 | $81,357 | +19.6% | 13,537 | +15.8% | 0.00% | – |
| Q3 2022 | $68,000 | -20.0% | 11,688 | -17.9% | 0.00% | – |
| Q2 2022 | $85,000 | +30.8% | 14,237 | +11.9% | 0.00% | – |
| Q1 2022 | $65,000 | +103.1% | 12,719 | -2.8% | 0.00% | – |
| Q4 2021 | $32,000 | -15.8% | 13,082 | +1.6% | 0.00% | – |
| Q3 2021 | $38,000 | +11.8% | 12,877 | -4.8% | 0.00% | – |
| Q2 2021 | $34,000 | +6.2% | 13,523 | +21.2% | 0.00% | – |
| Q1 2021 | $32,000 | -11.1% | 11,157 | +0.3% | 0.00% | – |
| Q4 2020 | $36,000 | +56.5% | 11,120 | +5.4% | 0.00% | – |
| Q3 2020 | $23,000 | +76.9% | 10,547 | -5.4% | 0.00% | – |
| Q2 2020 | $13,000 | -40.9% | 11,150 | -53.7% | 0.00% | – |
| Q1 2020 | $22,000 | +175.0% | 24,092 | +145.8% | 0.00% | – |
| Q3 2019 | $8,000 | – | 9,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 4,068,191 | $4,719,000 | 9.14% |
| CAXTON CORP | 619,460 | $719,000 | 0.76% |
| BVF INC/IL | 6,929,690 | $8,038,000 | 0.50% |
| NEA Management Company, LLC | 7,140,450 | $8,283,000 | 0.33% |
| Orbimed Advisors | 9,520,600 | $11,044,000 | 0.16% |
| Renaissance Technologies | 2,103,792 | $2,440,000 | 0.00% |
| Paloma Partners Management Co | 30,289 | $35,000 | 0.00% |
| WEDBUSH SECURITIES INC | 12,600 | $15,000 | 0.00% |
| HRT FINANCIAL LP | 19,710 | $22,000 | 0.00% |
| FIRST MANHATTAN CO. LLC. | 33 | $0 | 0.00% |